Tech Company Financing Transactions
IDRx Funding Round
On 8/2/2022, IDRx raised $122 million in Series A funding from Andreessen Horowitz, Casdin Capital and Forge Life Science Partners.
Transaction Overview
Company Name
Announced On
8/2/2022
Transaction Type
Venture Equity
Amount
$122,000,000
Round
Series A
Investors
Andreessen Horowitz (Lead Investor)
Casdin Capital (Lead Investor)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
52 Court St.
Plymouth, MA 02360
USA
Plymouth, MA 02360
USA
Phone
Undisclosed
Website
Email Address
Overview
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Founded in 2022, IDRx's leadership team has extensive experience in drug development, and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ben Auspitz
Chief Operating Officer
Jessica Christo
VP - Operations
Debbie Johnson
VP - Product Management
Vic Kadambi
VP - Regulatory Affairs
Shrenik Desai
Browse more venture capital transactions:
Prev: 8/2/2022: Taibang Biologic Group venture capital transaction
Next: 8/2/2022: Sprig Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs